Each quarter, ASCO’s experts review the leading journals, including the Journal of Clinical Oncology, to compile the most relevant, practice-changing science in Hematological Malignancies. Reviews are presented in a didactic slide format, with audio commentary and links to references and resources and will focus on the following areas: translational science, clinical trials, reviews, guidelines, and editorials.
Articles covered in this quarter’s review include:
- Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). Mamot C, et al. J Clin Oncol. 2015; Epub Jul 6.
- Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. Casulo C, et al. J Clin Oncol. 2015; Epub Jun 29
- Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. O’Connor OA, et al. J Clin Oncol. 2015; Epub Jun 22.
- Explain the role of histone deacetylases inhibitor as new targeted therapy for T cell lymphoma
- Recognize treatment of relapse of T cell lymphoma is an unmet need with median survival of six months
- Incorporate new drugs for a better management of peripheral T cell lymphomas
- Apply knowledge learned to enhance the care delivered to patients with hematologic malignancies
- AMA PRA Category 1 Credits™
- Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
- Certificate of Completion may be used to document participation, but no credit will be conferred.
- This course expires on September 30, 2018. Participants must complete all necessary course components by this date to receive credit.